Research output per year
Research output per year
Search results
-
2024
Infections in patients with mantle cell lymphoma
Abalo, K. D., Ekberg, S., Andersson, T. M. L., Pahnke, S., Albertsson-Lindblad, A., Smedby, K. E., Jerkeman, M. & Glimelius, I., 2024 Jul, In: HemaSphere. 8, 7, e121.Research output: Contribution to journal › Article › peer-review
Open Access -
2023
Secondary malignancies among mantle cell lymphoma patients
Abalo, K. D., Smedby, K. E., Ekberg, S., Eloranta, S., Pahnke, S., Albertsson-Lindblad, A., Jerkeman, M. & Glimelius, I., 2023 Dec, In: European Journal of Cancer. 195, 113403.Research output: Contribution to journal › Article › peer-review
Open Access -
Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCL complete Project
Jerkeman, M., Ekberg, S., Glimelius, I., Albertsson-Lindblad, A., Entrop, J. P., Ellin, F., Sonnevi, K., Lewerin, C., Brandefors, L. & Smedby, K. E., 2023 Aug, In: HemaSphere. 7, 8, p. E928Research output: Contribution to journal › Article › peer-review
Open Access -
Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation
Ekberg, S., Smedby, K. E., Albertsson-Lindblad, A., Jerkeman, M., Weibull, C. E. & Glimelius, I., 2023 Mar 14, In: Blood Advances. 7, 5, p. 866-874 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
2022
Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience
Lindberg, Å., Eskelund, C. W., Albertsson-Lindblad, A., Kolstad, A., Laurell, A., Räty, R., Grønbæk, K., Geisler, C. H. & Jerkeman, M., 2022, In: Hematological Oncology. 40, 1, p. 23-31Research output: Contribution to journal › Article › peer-review
Open Access -
2021
Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival
Glimelius, I., Smedby, K. E., Albertsson-Lindblad, A., Crowther, M. J., Eloranta, S., Jerkeman, M. & Weibull, C. E., 2021, In: Blood Advances. 5, 6, p. 1638-1647 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
2019
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
Albertsson-Lindblad, A., Freiburghaus, C., Jerkeman, M. & Ek, S., 2019 Aug 6, In: Experimental Hematology and Oncology. 8, 1, 16.Research output: Contribution to journal › Article › peer-review
Open Access -
Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?
Albertsson-Lindblad, A. & Jerkeman, M., 2019, In: Annals of Lymphoma. 3, 2, p. 1-15Research output: Contribution to journal › Article › peer-review
Open Access -
2016
Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4
Albertsson-Lindblad, A., Kolstad, A., Laurell, A., Räty, R., Grønbæk, K., Sundberg, J., Pedersen, L. B., Ralfkiær, E., Karjalainen-Lindsberg, M.-L., Sundström, C., Ehinger, M., Geisler, C. & Jerkeman, M., 2016 Jun 27, In: Blood. 128, 14, p. 1814-1820Research output: Contribution to journal › Article › peer-review
Open AccessFile -
2014
Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
Abrahamsson, A., Albertsson Lindblad, A., Brown, P. N., Baumgartner-Wennerholm, S., Pedersen, L. M., D'Amore, F., Nilsson-Ehle, H., Jensen, P., Pedersen, M., Geisler, C. H. & Jerkeman, M., 2014, In: Blood. 124, 8, p. 1288-1295Research output: Contribution to journal › Article › peer-review